Boehringer Ingelheim Pharmaceuticals, Inc.

Novartis Ag

Thomas A Gilmore

Eugene R Hickey

Pier Francesco Cirillo

John R Regan

David S Thomson

John Robert Proudfoot

Hidenori Takahashi

Daniel Kuzmich

Ji Wang

Rajashehar Betageri

Doris Riether

Neil Moss

Hossein Razavi

Steffen Breitfelder

Alan David Swinamer

Christian Hanke Justus Joachim Harcken

Denice Mary Spero

Charles Lawrence Cywin

Usha R Patel

Younes Bekkali

Lin-Hua Zhang

Rajiv Sharma

Christopher Pargellis

Weimin Liu

Renee M Zindell

Sanxing Sun

Gary Mark Coppola

Mario G Cardozo

Taeyoung Yoon

Peter Allen Nemoto

Rajashekhar Betageri

Moo Je Sung

Thomas M Kirrane

Monica H Moriak

Thomas Martin Kirrane

The present invention provides compounds of the following structure;A-L1-B&#x2014;C-Dthat are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.

Organic compounds

Compounds of Formula (IA) wherein R, R, R, Rand Rare as defined herein for Formula (IA), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof

Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

Compounds of Formula (IA) and Formula (IB) wherein R, R, R, R, R, and Rare as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.

Compounds useful as anti-inflammatory agents

Compounds of Formula (IA) and Formula (IB)wherein R, R, R, R, R, and Rare as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Compounds according to the following formula (I):wherein the variables Q and Rto Rare as described herein, which reversibly inhibit the cysteine proteases, such as cathepsins K, S, F, L and B; pharmaceutical compositions containing such compounds, and method of treating diseases and pathological conditions exacerbated by these cysteine proteases such as, but not limited to rheumatoid arthritis, multiple sclerosis and other autoimmune diseases, osteoporosis, asthma, Alzheimer's disease, atherosclerosis and endometriosis.

Cyanamides useful as reversible inhibitors of cysteine proteases

Compounds of Formula (I)wherein R, R, R, R, R, R, X, Y, and n are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Disclosed are novel aromatic heterocyclic compounds of the formula(I) wherein Ar,,Ar,,L,Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Method of treating cytokine mediated diseases or conditions

Disclosed are novel aromatic heterocyclic compounds of the formula (I) wherein Ar,, Ar,, L, Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Aromatic heterocyclic compound as antiinflammatory agents

Novel aromatic heterocyclic compounds inhibit cytokines production involved in immunoregulation and inflammation such as interleukin-1 and tumor necrosis factor production. The compounds are therefore useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases.

Aromatic heterocyclic compounds and their use as anti-inflammatory agents

Growing community of inventors

Salem, MA, United States of America

Thomas A Gilmore